NDA 203971 · Bayer Hlthcare
Xofigo
Radium Ra-223 Dichloride · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
May 15, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
65
9 Phase 3, 3 recruiting
FAERS reports
5,055
4,481 serious, 1,036 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 2, 2026.
Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. ( 1 )
Mechanism: The active moiety of Xofigo is the alpha particle-emitting isotope radium-223 (as radium Ra 223 dichloride), which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases (see Table 2). The high linear energy transfer of alpha particles (80 keV/micrometer) leads to a high frequency of double-strand DNA breaks in adjacent cells including tumor cells, osteoblasts and osteoclasts, resulting in an anti-tumor effect on bone metastases. The alpha particle range from radium-223 dichloride is less than 100 micrometers (less...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 15, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLabelSummary Review
1 products under this application
- XOFIGO · RADIUM RA-223 DICHLORIDE 162mCi/6ML (27mCi/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Radium Ra-223 Dichloride" as an intervention, any sponsor and status, largest first.
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00699751 · 921 participants · Start Jun 12, 2008 · Primary completion Jul 15, 2011
Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Placebo and 1 more · For: Hormone Refractory Prostate Cancer; Bone Metastases
Sites: Los Angeles, California; Roseville, California; Tampa, Florida · 134 sites in all
BayerBayer (BAYRY)
NCT02043678 · 806 participants · Start Mar 30, 2014 · Primary completion Feb 15, 2018
Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Matching placebo (normal saline) and 2 more · For: Prostatic Neoplasms
Sites: Anchorage, Alaska; Tucson, Arizona; Oceanside, California · 163 sites in all
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPivotal-lookingRecruiting
Karolinska InstitutetAcademic, hospital or other
NCT03903835 · 750 participants (planned) · Start Feb 1, 2019 · Primary completion Dec 2026
Drug: Enzalutamide Oral Capsule; Abiraterone Oral Tablet and 8 more · For: Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Aalst, Belgium; Antwerp, Belgium; Bruges, Belgium · 32 sites in all
- Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone MetastasesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01618370 · 705 participants · Start Jul 22, 2012 · Primary completion Aug 13, 2014
Drug: Radium-223 dichloride (BAY88-8223) · For: Prostatic Neoplasms
Sites: Bruges, Belgium; Bruxelles - Brussel, Belgium; Edegem, Belgium · 215 sites in all
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07611110 · 670 participants (planned) · Start May 4, 2026 · Primary completion Jun 4, 2029
Drug: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]); Cabazitaxel and 6 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Duarte, California · 151 sites in all
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)Pivotal-lookingActive, not recruiting
BayerBayer (BAYRY)
NCT04597125 · 654 participants · Start Nov 9, 2020 · Primary completion Nov 21, 2025
Drug: Radium-223 dichloride (Xofigo, BAY88-8223); ARPI therapy · For: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Sites: Castle Hill, Australia; Gosford, Australia; Kingswood, Australia · 117 sites in all
- Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal TherapyPivotal-lookingStatus unknown
Amsterdam UMC, location VUmcAcademic, hospital or other
NCT03458559 · 402 participants (planned) · Start May 16, 2018 · Primary completion May 16, 2022
Drug: Radium-223 chloride; Rhenium-188-HEDP · For: Prostate Cancer Metastatic to Bone
Sites: Amsterdam, Netherlands
- Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the BonePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02023697 · 391 participants · Start Mar 10, 2014 · Primary completion Mar 1, 2017
Drug: Radium-223 dichloride (Xofigo, BAY88-8223) · For: Prostatic Neoplasms
Sites: Scottsdale, Arizona; New Haven, Connecticut; Fort Myers, Florida · 68 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- prostatic specific antigen increased482
- death450
- hormone-refractory prostate cancer436
- metastases to bone327
- general physical health deterioration310
- anaemia285
- fatigue278
- haemoglobin decreased243
- nausea239
- pain234
- disease progression226
- prostate cancer221
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 77 |
| 2014 | 264 |
| 2015 | 365 |
| 2016 | 417 |
| 2017 | 697 |
| 2018 | 719 |
| 2019 | 581 |
| 2020 | 363 |
| 2021 | 496 |
| 2022 | 309 |
| 2023 | 230 |
| 2024 | 262 |
| 2025 | 168 |
| 2026 | 107 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Kluetz PG, Pierce W, Maher VE, et al. · Clin Cancer Res 2014 · Clinical Trial, Phase III, Randomized Controlled Trial
- Where Do We See Alpha Emitters in Clinical Practice? A Radiation Oncology Perspective.
O'Sullivan JM · J Med Imaging Radiat Sci 2019 · Systematic Review
- Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S · Expert Opin Drug Saf 2015 · Clinical Trial, Phase III, Randomized Controlled Trial
- Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature.
Norum J, Traasdahl ER, Totth A, et al. · Glob J Health Sci 2015 · Case Reports, Systematic Review
- Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden.
Miederer M, Thomas C, Beck J, et al. · Nuklearmedizin 2015 · Clinical Trial
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.